Optimising dry powder inhaler programmes through formulation

被引：0

作者：

Willis, Nikki ^{[1
]}

机构：

[1] Pharmaceutical Development, Vectura

来源：

Manufacturing Chemist | 2021年 / 92卷 / 10期

关键词：

Drug products;

D O I：

暂无

中图分类号：

R96 [药理学]; R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ; 100706 ;

摘要：

The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without having to wait for them to be absorbed through the gut.

引用

页码：14 / 16

共 50 条

[1] Evolution of dry powder inhaler design, formulation, and performance
Newman, SP
Busse, WW
RESPIRATORY MEDICINE, 2002, 96 (05) : 293 - 304
[2] In vitro dry powder inhaler formulation performance considerations
Ziffels, Susanne
Bemelmans, Norman L.
Durham, Phillip G.
Hickey, Anthony J.
JOURNAL OF CONTROLLED RELEASE, 2015, 199 : 45 - 52
[3] INNOVATION IN MANUFACTURING AS APPLIED TO DRY POWDER INHALER FORMULATION
Wyatt, David A.
Koner, Jasdip S.
Dahmash, Eman Z.
Mohammed, Afzal R.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2019, 32 (02) : A18 - A18
[4] Development of Liposomal Salbutamol Sulfate Dry Powder Inhaler Formulation
Huang, Wen-Hua
Yang, Zhi-Jun
Wu, Heng
Wong, Yuen-Fan
Zhao, Zhong-Zhen
Liu, Liang
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (03) : 512 - 517
[5] Formulation of Biopharmaceutical Dry Powder Inhaler Using the Void Forming Index (VFI) to Detect and Avoid Powder Caking in Dry Powder Inhaler Formulations
Maruyama, Sunao
Miyajima, Makoto
Yonemochi, Etsuo
CHEMICAL & PHARMACEUTICAL BULLETIN, 2022, 70 (04) : 245 - 253
[6] Development of liposomal amphotericin B dry powder inhaler formulation
Shah, SP
Misra, A
DRUG DELIVERY, 2004, 11 (04) : 247 - 253
[7] Air permeability of powder: A potential tool for Dry Powder Inhaler formulation development
Le, V. N. P.
Robins, E.
Flament, M. P.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2010, 76 (03) : 464 - 469
[8] Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery
Rashid, Md Abdur
Elgied, Amged Awad
Alhamhoom, Yahya
Chan, Enoch
Rintoul, Llew
Allahham, Ayman
Islam, Nazrul
PHARMACEUTICS, 2019, 11 (05):
[9] FORMULATION OPTIMIZATION AND PERFORMANCE OF THE MICRONIZER - A NOVEL ACTIVE DRY POWDER INHALER
Wagenseil, L.
Steckel, H.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2013, 26 (05) : A12 - A12
[10] Nanosized rods agglomerates as a new approach for formulation of a dry powder inhaler
Salem, H. F.
Abdelrahim, M. E.
Eid, K. Abo
Sharaf, M. A.
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2011, 6 : 311 - 320

← 1 2 3 4 5 →